Pharmaceutical products

Description

The contracting authorities currently source their pre-prepared radiopharmaceutical kits from external providers holding ‘Special’ licenses, who supply and deliver compounded radiopharmaceutical kits within a specified time and date to enable delivery of patient care and support operational effectiveness. The requirement covers the provision of the following radiopharmaceuticals: Tc99m (Technetium), MAA, HDP/HMDP, MAG3, DMSA, Sestamibi, Nanocolloid and Pertechnetate. These are provided in the form of multi injection vials. This notice is for an extension to the existing agreements held at both contracting authorities, in order to allow sufficient time and resource (in light of the Covid-19 pandemic) to re engage with the market and design a procurement strategy for a renewed agreement. It is the expectation of the contracting authorities that this will be awarded for an initial 12-month period, with an option to not exceed 18 months in total. The contracting authority currently sources their pre-prepared radiopharmaceutical kits from external providers holding ‘Special’ licenses, who supply and deliver compounded radiopharmaceutical kits within a specified time and date to enable delivery of patient care and support operational effectiveness. The requirement covers the provision of the following radiopharmaceuticals: Tc99m (Technetium), MAA, HDP/HMDP, MAG3, DMSA, Sestamibi, Nanocolloid and Pertechnetate. These are provided in the form of multi injection vials. This notice is for an extension to the existing agreements held at both contracting authorities, in order to allow sufficient time and resource (in light of the Covid-19 pandemic) to re engage with the market and design a procurement strategy for a renewed agreement. The contracting authority currently sources their pre-prepared radiopharmaceutical kits from external providers holding ‘Special’ licenses who supply and deliver compounded radiopharmaceutical kits within a specified time and date to enable delivery of patient care and support operational effectiveness. The requirement covers the provision of the following radiopharmaceuticals: Tc99m (Technetium), MAA, HDP/HMDP, MAG3, DMSA, Sestamibi, Nanocolloid and Pertechnetate. These are provided in the form of multi injection vials. This notice is for an extension to the existing agreements held at both contracting authorities, in order to allow sufficient time and resource (in light of the Covid-19 pandemic) to re engage with the market and design a procurement strategy for a renewed agreement.